Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25832160 | 0.83 | CYP19A1 (0.55) | CYP19A1MAOBHTTPBRM1 | |
| SCHEMBL68075 | 0.78 | PBRM1 (0.67) | CYP19A1MAOBARALDH1A1MAPT | |
| SCHEMBL26966465 | 0.77 | HRH4 (0.42) | CYP19A1MAOBMAPTHCRTR2 | |
| SCHEMBL69423 | 0.74 | MAOB (0.55) | CYP19A1MAOBARALDH1A1MAPT | |
| SCHEMBL24897762 | 0.73 | GRM5 (0.45) | ARALDH1A1MAPTPKMHPGD | |
| SCHEMBL14741423 | 0.73 | PBRM1 (0.53) | CYP19A1MAOBARPBRM1S100A4 | |
| SCHEMBL25832144 | 0.72 | ALOX12 (0.41) | CYP19A1MAOBARALDH1A1MAPT | |
| SCHEMBL22162362 | 0.72 | CYP19A1 (0.39) | CYP19A1MAOBAR | |
| SCHEMBL22162363 | 0.72 | CYP19A1 (0.39) | CYP19A1MAOBAR | |
| SCHEMBL69670 | 0.71 | MAOB (0.50) | CYP19A1MAOBARMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | HAVCR2, HPD, CYP24A1 | CYP19A1 1123/4885MAOB 929/4885AR 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.